-+ 0.00%
-+ 0.00%
-+ 0.00%

BLOSSOMHILL THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR BH-30643, A MACROCYCLIC OMNI-EGFR™ INHIBITOR FOR THE TREATMENT OF ADVANCED EGFR C797S-POSITIVE NSCLC

Reuters·08/18/2026 11:00:00

Please log in to view news